Fei Su
Affiliations: | Discovery Biology | Roche Pharmaceuticals, Branchburg, NJ, United States |
Google:
"Fei Su"Mean distance: 17.25 (cluster 32) | S | N | B | C | P |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Fan Y, Wu G, Su F, et al. (2016) Lipase oriented-immobilized on dendrimer-coated magnetic multi-walled carbon nanotubes toward catalyzing biodiesel production from waste vegetable oil Fuel. 178: 172-178 |
| Higgins B, Kolinsky KD, Schostack K, et al. (2012) Efficacy of vemurafenib (V), a selective (V600E)BRAF inhibitor, as monotherapy or in combination with erlotinib (Erl) or erbitux (Erb) and irinotecan (Iri) doublets and triplets in a colorectal cancer (CRC) xenograft model. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 494 |
| Higgins B, Kolinsky KD, Yang H, et al. (2012) Efficacy of vemurafenib, a selective BRAF(V600E) inhibitor, in combination with a MEK inhibitor in BRAF(V600E) colorectal cancer models. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 488 |
| Baudy AR, Dogan T, Flores-Mercado JE, et al. (2012) FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973. Ejnmmi Research. 2: 22 |
| Su F, Viros A, Milagre C, et al. (2012) RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. The New England Journal of Medicine. 366: 207-15 |
| Su F, Bradley WD, Wang Q, et al. (2012) Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. Cancer Research. 72: 969-78 |
| Yang H, Higgins B, Kolinsky K, et al. (2012) Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Research. 72: 779-89 |
| Baudy AR, Dogan T, Flores JE, et al. (2012) Abstract 911: Vemurafenib FDG-PET preclinical imaging outcomes across BRAF V600E mutant and resistant tumors Cancer Research. 72: 911-911 |
| Yang H, Higgins B, Kolinsky K, et al. (2012) Abstract 2156: Preclinical combinations of vemurafenib, a selective BRAF inhibitor, with other targeted therapies in BRAFV600Ecolorectal cancer models Cancer Research. 72: 2156-2156 |
| Su F, Yang H, Higgins B, et al. (2011) Molecular mechanisms underlying disease relapse on treatment with selective BRAF inhibitor vemurafenib (PLX4032). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 8517 |